Strategic partnerships Pall actively collaborates with industry leaders (G-CON Manufacturing, WuXi Biologics, Emirates Airline) to enable turnkey bioprocessing and advanced filtration solutions, presenting cross-sell opportunities into biotech manufacturing, bioprocessing facilities, and global aviation refurbishment programs.

Continuous processing Recent focus on continuous processing for monoclonal antibodies and joint lab work with WuXi Biologics signals a market push toward integrated, end-to-end purification and filtration solutions across biopharma production lines.

Leadership transition Appointment of a new president in 2026 may indicate strategic realignment and renewed sales focus; proactively engage to align Pall’s updated priorities with customer expansion plans in filtration, separation, and purification.

Aviation reliability decade-long partnership with Emirates Airline highlights Pall’s value in reducing downtime and boosting passenger comfort; explore expansion into aircraft cabin, ground service, and maintenance reliability markets with filtration and purification needs.

Ceramic membrane growth Launch of Membralox GP-IC ceramic membrane systems in 2025 points to advanced filtration capabilities; target high-purity, high-capacity processing environments in biotech, chemical processing, and industrial filtration sectors seeking robust membrane technologies.